Agenus | AGEN - Net Income

Stock Price
3.03
Daily Change
-0.17 -5.31%
Monthly
9.39%
Yearly
25.73%
Q1 Forecast
3.23

Agenus reported $-25.27M in Net Income for its fiscal quarter ending in March of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Agenus USD -25.27M 20.59M Mar/2025
Amgen USD 1.33B 1.88B Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Celldex Therapeutics USD -81.32M 14.27M Dec/2025
CSL USD 401M 96.5M Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Gilead Sciences USD 2.18B 869M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Glaxosmithkline GBP 2.71B 1.27B Sep/2025
Incyte USD 299.28M 124.89M Dec/2025
J&J USD 5.12B 36M Dec/2025
Jiangsu Hengrui CNY 1.3B 1.27B Sep/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
MacroGenics USD 16.82M 53.07M Sep/2025
Merck EUR 902M 250M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Northwest Biotherapeutics USD -19.37M 1.5M Sep/2024
Novartis USD 3.93B 96M Sep/2025
Novavax USD -121.3M 283.68M Sep/2024
Pfizer USD -1.65B 5.19B Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Veracyte USD 41.15M 22.01M Dec/2025